By Fineline Cube French pharmaceutical major Sanofi (NASDAQ: SNY) has announced the official market launch of Soliqua (insulin glargine, lixisenatide) in China, targeting adults with type 2 diabetes (T2DM) who struggle with poor blood glucose control. This product can be integrated with other oral hypoglycemic drugs, along with diet and exercise, to enhance blood glucose management.
Addressing the Diabetes Burden in China
China is home to 140 million diabetes patients, approximately 50% of whom do not meet the standard for blood glucose control. Among these patients, over 50% have fasting blood sugar levels that exceed the standard, and 80% experience a rise in postprandial blood sugar. This combination of high fasting and postprandial blood sugar levels increases the risk of complications.
The Benefits of Soliqua
Insulin glargine in Soliqua mimics the natural secretion of insulin in the human body, effectively controlling 24-hour basal blood sugar levels. Lixisenatide, the other component, promotes insulin secretion in response to blood sugar increases during meals, reducing sugar peaks, delaying gastric emptying, controlling appetite, and strengthening postprandial blood sugar control. The dual-action formula of Soliqua is designed to balance both fasting and postprandial blood sugar levels, promoting overall blood sugar compliance. Numerous clinical studies have confirmed that Soliqua provides hypoglycemic effects while minimizing the risk of hypoglycemia and weight gain.
Rapid Market Launch by Sanofi
Sanofi has achieved an expedited market launch for the injectable Soliqua, taking only four months from approval to market availability—a process that can typically take up to one year. This swift transition underscores Sanofi’s commitment to bringing innovative diabetes treatments to the Chinese market swiftly.-Fineline Info & Tech